All trials
NCT05469360PHASE1RECRUITING

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

✨ Plain-English version on the way · ~2 days

We're still translating this one. In a couple of days, you'll see what this trial actually tests — and whether it matters for APOE4 carriers like you. For now, here's the sponsor's own description:

Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)
Read full record on ClinicalTrials.gov

Eligibility check — Phoenix members

Phoenix members see for THIS trial:

  • APOE genotype match
  • Cognitive status fits inclusion
  • Specific exclusions flagged
  • Distance to nearest site
Check my eligibility — become a member
Sites
10 locations
Start
2023-02-23

Interventions tested

  • DRUGNIO752
  • DRUGNIO752
  • DRUGMatching placebo
  • DRUGNIO752
  • DRUGNIO752
  • DRUGNIO752
  • DRUGMatching placebo
View full record on ClinicalTrials.gov

We use cookies to enhance your experience.